Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Drug Profile

Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Alternative Names: ADP A2M4; ADP‑A2M4CD8; MAGE-A4 SPEAR T-cell therapy; MAGE-A4 TCR; MAGE-A4-SPEAR-T-cell-therapy-Adaptimmune; MAGE-A4ᶜ¹º³²T

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; University of Texas M. D. Anderson Cancer Center
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myxoid liposarcoma; Synovial sarcoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Haematological malignancies

Most Recent Events

  • 14 Jan 2020 Efficacy and adverse events data from the phase I SURPASS trial in Solid tumours released by Adaptimmune
  • 03 Dec 2019 Melanoma-associated antigen A4-specific T-cells - Adaptimmune receives Regenerative Medicine Advanced Therapy (RMAT) status for Synovial sarcoma in USA
  • 16 Nov 2019 Updated efficacy and adverse events data from a phase I trial in Solid tumours released by Adaptimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top